Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

Abstract

A B S T R A C T PurposeTo determine long-term outcomes in a clinical trial evaluating the role of taxane type and schedule in operable breast cancer and evaluate the impact of obesity and black race on outcome. Patients and MethodsA total of 4,954 eligible women with stage II to III breast cancer treated with four cycles of doxorubicin plus cyclophosphamide were randomly assigned to receive paclitaxel or docetaxel every 3 weeks for four doses or weekly for 12 doses using a 2 ϫ 2 factorial design. The primary end point was disease-free survival (DFS). Results are expressed as hazard ratios (HRs) from Cox proportional hazards models. All P values are two sided. ResultsWhen compared with the standard every-3-week paclitaxel arm, after a median follow-up of 12.1 years, DFS significantly improved and overall survival (OS) marginally improved only for the weekly paclitaxel (HR, 0.84; P ϭ .011 and HR, 0.87; P ϭ .09, respectively) and every-3-week docetaxel arms (HR, 0.79; P ϭ .001 and HR, 0.86; P ϭ .054, respectively). Weekly paclitaxel improved DFS and OS (HR, 0.69; P ϭ .010 and HR, 0.69; P ϭ .019, respectively) in triple-negative breast cancer. For hormone receptor-positive, human epidermal growth factor receptor 2-nonoverexpressing disease, no experimental arm improved OS, and black race and obesity were associated with increased risk of breast cancer recurrence and death. ConclusionImproved outcomes initially observed for weekly paclitaxel were qualitatively similar but quantitatively less pronounced with longer follow-up, although exploratory analysis suggested substantial benefit in triple-negative disease. Further research is required to understand why obesity and race influence clinical outcome in hormone receptor-positive disease.

Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer

“…Defined as a body mass index (BMI) of 30 kg/m 2 or greater, obesity is now a leading modifiable contributor to breast cancer mortality worldwide (6-9). Specifically, obesity is associated with increased risk of relapse and decreased overall survival for patients with early-stage breast cancer (10-15). However, specific strategies that target obesity have been limited by an incomplete understanding of the complex biologic mechanisms underlying the obesity-cancer relationship.…”

Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates

“…When both weekly regimens were compared with the other 2 q3w regimens, no significant differences were found. A long-term data analysis of the ECOG 1199 trial has been published showing that weekly paclitaxel retained its OS benefit only for triple-negative patients (hazard ratio (HR) 0.69; p = 0.019) [16]. …”

Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients

“…Results of a randomized trial with 12 years of follow-up reported weekly paclitaxel was superior to every 3 weeks, with statistically-significant longer disease-free and overall survival in triple negative breast cancer patients 32. The genetic abnormalities in triple negative breast cancer have been shown to be similar to those in high-grade serous ovarian cancer 33.…”